Microvascular lesions of diabetic retinopathy: Clues towards understanding pathogenesis?

Eye

Volumn 23, Issue 7, 2009, Pages 1496-1508

  Curtis, T M ^a   Gardiner, T A ^a   Stitt, A W ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Blood flow; Diabetes; Diabetic retinopathy; Haemodynamics; Hypoxia; Ischaemia

Indexed keywords

PIMONIDAZOLE; VASCULOTROPIN;

ANIMAL MODEL; BASEMENT MEMBRANE; BLINDNESS; BLOOD RETINA BARRIER; CAPILLARY; CELL DEATH; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; DIABETIC RETINOPATHY; FLUORESCENCE ANGIOGRAPHY; HEMODYNAMICS; HYPOXIA; INFLAMMATION; MICROANEURYSM; MICROVASCULAR ISCHEMIA; NONHUMAN; OXYGENATION; PATHOGENESIS; PERFUSION; PERICYTE; RETINA; RETINA BLOOD FLOW; RETINA BLOOD VESSEL OCCLUSION; RETINA MACULA EDEMA; RETINA NEOVASCULARIZATION; REVIEW; VISUAL IMPAIRMENT;

ANOXIA; DIABETES MELLITUS; DIABETIC RETINOPATHY; HEMODYNAMICS; HUMANS; MICROCIRCULATION; REGIONAL BLOOD FLOW; RETINAL VESSELS;

EID: 67749088340     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.108     Document Type: Review

References (105)

1. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21(9): 1414-1431.
2. Klein R, Klein BE, Moss SE. The Wisconsin Epidemiological Study of Diabetic Retinopathy: a review. Diabetes Metab Rev 1989; 5(7): 559-570. (Pubitemid 19272666)
3. DCCT. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977-986.
4. UKPDS (UK Prospective Diabetes Study Group). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317(7160): 703-713.
5. Antonetti DA, Barber AJ, Bronson SK, Freeman WM, Gardner TW, Jefferson LS et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006; 55(9): 2401-2411.
6. Hancock HA, Kraft TW. Oscillatory potential analysis and ERGs of normal and diabetic rats. Invest Ophthalmol Vis Sci 2004; 45(3): 1002-1008.
7. Ewing FM, Deary IJ, Strachan MW, Frier BM. Seeing beyond retinopathy in diabetes: electrophysiological and psychophysical abnormalities and alterations in vision. Endocr Rev 1998; 19(4): 462-476.
8. Jackson GR, Owsley C. Visual dysfunction, neurodegenerative diseases, and aging. Neurol Clin 2003; 21(3): 709-728. (Pubitemid 36754063)
9. Gastinger MJ, Barber AJ, Khin SA, McRill CS, Gardner TW, Marshak DW. Abnormal centrifugal axons in streptozotocindiabetic rat retinas. Invest Ophthalmol Vis Sci 2001; 42(11): 2679-2685.
10. Martin PM, Roon P, Van Ells TK, Ganapathy V, Smith SB. Death of retinal neurons in streptozotocin-induced diabetic mice. Invest Ophthalmol Vis Sci 2004; 45(9): 3330-3336. (Pubitemid 39121873)
11. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998; 102(4): 783-791. (Pubitemid 28399611)
12. Park SH, Park JW, Park SJ, Kim KY, Chung JW, Chun MH et al. Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina. Diabetologia 2003; 46(9): 1260-1268.
13. Nishimura C, Kuriyama K. Alterations in the retinal dopaminergic neuronal system in rats with streptozotocin-induced diabetes. J Neurochem 1985; 45(2): 448-455. (Pubitemid 15233944)
14. Zeng XX, Ng YK, Ling EA. Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. Vis Neurosci 2000; 17(3): 463-471. (Pubitemid 30451626)
15. Agardh E, Bruun A, Agardh CD. Retinal glial cell immunoreactivity and neuronal cell changes in rats with STZ-induced diabetes. Curr Eye Res 2001; 23(4): 276-284. (Pubitemid 34161300)
16. Kusner LL, Sarthy VP, Mohr S. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase: a role in high glucose-induced apoptosis in retinal Muller cells. Invest Ophthalmol Vis Sci 2004; 45(5): 1553-1561. (Pubitemid 38859337)
17. Pannicke T, Iandiev I, Wurm A, Uckermann O, vom Hagen F, Reichenbach A et al. Diabetes alters osmotic swelling characteristics and membrane conductance of glial cells in rat retina. Diabetes 2006; 55(3): 633-639.
18. Puro DG. Diabetes-induced dysfunction of retinal Muller cells. Trans Am Ophthalmol Soc 2002; 100: 339-352.
19. Lieth E, Barber AJ, Xu B, Dice C, Ratz MJ, Tanase D et al. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes 1998; 47(5): 815-820. (Pubitemid 28201813)
20. Gardiner TA, Archer DB, Curtis TM, Stitt AW. Arteriolar involvement in the microvascular lesions of diabetic retinopathy: implications for pathogenesis. Microcirculation 2007; 14(1): 25-38. (Pubitemid 46321703)
21. Delaey C, Van dV. Regulatory mechanisms in the retinal and choroidal circulation. Ophthalmic Res 2000; 32(6): 249-256.
22. Wagener HP, Story DTD, Wilder RM. Retinitis in diabetes. N Engl J Med 1934; 211: 1131-1137.
23. Ballantyne AJ, Loewenstein A. The pathology of diabetic retinopathy. Trans Ophthalmol Soc UK 1943; 63: 95-113.
24. Skovborg F, Nielsen AV, Lauritzen E, Hartkopp O. Diameters of the retinal vessels in diabetic and normal subjects. Diabetes 1969; 18(5): 292-298.
25. Kohner EM, Hamilton AM, Saunders SJ, Sutcliffe BA, Bulpitt CJ. The retinal blood flow in diabetes. Diabetologia 1975; 11(1): 27-33.
26. Wong TY, Klein R, Sharrett AR, Schmidt MI, Pankow JS, Couper DJ et al. Retinal arteriolar narrowing and risk of diabetes mellitus in middle-aged persons. JAMA 2002; 287(19): 2528-2533. (Pubitemid 34517198)
27. Bursell SE, Clermont AC, Kinsley BT, Simonson DC, Aiello LM, Wolpert HA. Retinal blood flow changes in patients with insulin-dependent diabetes mellitus and no diabetic retinopathy. Invest Ophthalmol Vis Sci 1996; 37(5): 886-897.
28. Feke GT, Buzney SM, Ogasawara H, Fujio N, Goger DG, Spack NP et al. Retinal circulatory abnormalities in type 1 diabetes. Invest Ophthalmol Vis Sci 1994; 35(7): 2968-2975. (Pubitemid 24186398)
29. Clermont AC, Aiello LP, Mori F, Aiello LM, Bursell SE. Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy. Am J Ophthalmol 1997; 124(4): 433-446. (Pubitemid 27425869)
30. Grunwald JE, Riva CE, Baine J, Brucker AJ. Total retinal volumetric blood flow rate in diabetic patients with poor glycemic control. Invest Ophthalmol Vis Sci 1992; 33(2): 356-363.
31. Patel V, Rassam S, Newsom R, Wiek J, Kohner E. Retinal blood flow in diabetic retinopathy. BMJ 1992; 305(6855): 678-683.
32. Bertram B, Wolf S, Fiehofer S, Schulte K, Arend O, Reim M. Retinal circulation times in diabetes mellitus type 1. Br J Ophthalmol 1991; 75(8): 462-465.
33. Bursell SE, Clermont AC, Shiba T, King GL. Evaluating retinal circulation using video fluorescein angiography in control and diabetic rats. Curr Eye Res 1992; 11(4): 287-295.
34. Lorenzi M, Feke GT, Cagliero E, Pitler L, Schaumberg DA, Berisha F et al. Retinal haemodynamics in individuals with well-controlled type 1 diabetes. Diabetologia 2008; 51(2): 361-364.
35. Clermont AC, Bursell SE. Retinal blood flow in diabetes. Microcirculation 2007; 14(1): 49-61.
36. Stitt AW, Curtis TM. Advanced glycation and retinal pathology during diabetes. Pharmacol Rep 2005; 57(Suppl): 156-168.
37. Tilton RG, Chang K, Pugliese G, Eades DM, Province MA, Sherman WR et al. Prevention of hemodynamlemma and vascular albumin filtration changes in diabetic rats by aldose reductase inhibitors. Diabetes 1989; 38(10): 1258-1270. (Pubitemid 19247421)
38. Sun W, Oates PJ, Coutcher JB, Gerhardinger C, Lorenzi M. A selective aldose reductase inhibitor of a new structural class prevents or reverses early retinal abnormalities in experimental diabetic retinopathy. Diabetes 2006; 55(10): 2757-2762. (Pubitemid 44923674)
39. Curtis TM, Scholfield CN. The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy. Diabetes Metab Res Rev 2004; 20(1): 28-43. (Pubitemid 38196246)
40. Obrosova IG, Minchenko AG, Marinescu V, Fathallah L, Kennedy A, Stockert CM et al. Antioxidants attenuate early up regulation of retinal vascular endothelial growth factor in streptozotocin-diabetic rats. Diabetologia 2001; 44(9): 1102-1110. (Pubitemid 32835501)
41. Kowluru RA, Atasi L, Ho YS. Role of mitochondrial superoxide dismutase in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci 2006; 47(4): 1594-1599. (Pubitemid 46780770)
42. Tooke J. Possible pathophysiological mechanisms for diabetic angiopathy in type 2 diabetes. J Diabetes Complications 2000; 14(4): 197-200. (Pubitemid 30686255)
43. Schmetterer L, Wolzt M. Ocular blood flow and associated functional deviations in diabetic retinopathy. Diabetologia 1999; 42(4): 387-405. (Pubitemid 29148397)
44. Miyata T, van Ypersele de Strihou C. Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors: implication of radical scavenging and transition metal chelation in inhibition of advanced glycation end product formation. Arch Biochem Biophys 2003; 419(1): 50-54. (Pubitemid 37272159)
45. Bhatwadekar A, Stitt AW. AGEs and RAGE inhibitors in the treatment of diabetic retinopathy. Expert Rev Ophthalmol 2007; 2(1): 105-120.
46. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998; 47(6): 859-866. (Pubitemid 28255657)
47. Curtis TM, Scholfield CN. The role of lipids and protein kinase Cs in the pathogenesis of diabetic retinopathy. Diabetes Metab Res Rev 2004; 20(1): 28-43. (Pubitemid 38196246)
48. Bursell SE, Takagi C, Clermont AC, Takagi H, Mori F, Ishii H et al. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats. Invest Ophthalmol Vis Sci 1997; 38(13): 2711-2720. (Pubitemid 28009392)
49. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272(5262): 728-731. (Pubitemid 26000279)
50. Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 2006; 47(1): 86-92. (Pubitemid 46780799)
51. Davis MD, Sheetz MJ, Aiello LP, Milton RC, Danis RP, Zhi X et al. PKC-DRS2 Study Group. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema. Invest Ophthalmol Vis Sci 2009; 50(1): 1-4.
52. Scholfield CN, McGeown JG, Curtis TM. Cellular physiology of retinal and choroidal arteriolar smooth muscle cells. Microcirculation 2007; 14(1): 11-24.
53. 2+-activated potassium beta 1 channel subunit in retinal arteriolar smooth muscle. Circ Res 2007 100(5): 703-711.
54. Alder VA, Su EN, Yu DY, Cringle SJ, Yu PK. Diabetic retinopathy: early functional changes. Clin Exp Pharmacol Physiol 1997; 24(9-10): 785-788.
55. Linsenmeier RA, Braun RD, McRipley MA, Padnick LB, Ahmed J, Hatchell DL et al. Retinal hypoxia in long-term diabetic cats. Invest Ophthalmol Vis Sci 1998; 39(9): 1647-1657.
56. Dean FM, Arden GB, Dornhorst A. Partial reversal of protan and tritan colour defects with inhaled oxygen in insulin dependent diabetic subjects. Br J Ophthalmol 1997; 81(1): 27-30.
57. Harris A, Arend O, Danis RP, Evans D, Wolf S, Martin BJ. Hyperoxia improves contrast sensitivity in early diabetic retinopathy. Br J Ophthalmol 1996; 80(3): 209-213. (Pubitemid 26090347)
58. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001; 158(1): 147-152. (Pubitemid 32096479)
59. Nishiwaki H, Ogura Y, Kimura H, Kiryu J, Honda Y. Quantitative evaluation of leukocyte dynamics in retinal microcirculation. Invest Ophthalmol Vis Sci 1995; 36(1): 123-130.
60. Kunt T, Forst T, Fruh B, Flohr T, Schneider S, Harzer O et al. Binding of monocytes from normolipidemic hyperglycemic patients with type 1 diabetes to endothelial cells is increased in vitro. Exp Clin Endocrinol Diabetes 1999; 107(4): 252-256. (Pubitemid 29322138)
61. Schroder S, Palinski W, Schmid-Schonbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 1991; 139(1): 81-100.
62. Delaey C, Boussery K, Van de Voorde J. A retinal-derived relaxing factor mediates the hypoxic vasodilation of retinal arteries. Invest Ophthalmol Vis Sci 2000; 41(11): 3555-3560. (Pubitemid 30774947)
63. Yoshida A, Feke GT, Morales-Stoppello J, Collas GD, Goger DG, McMeel JW. Retinal blood flow alterations during progression of diabetic retinopathy. Arch Ophthalmol 1983; 101(2): 225-227. (Pubitemid 13186764)
64. Gottfredsdottir MS, Stefansson E, Jonasson F, Gislason I. Retinal vasoconstriction after laser treatment for diabetic macular edema. Am J Ophthalmol 1993; 115(1): 64-67. (Pubitemid 23019040)
65. Rogers SL, Tikellis G, Cheung N, Tapp R, Shaw J, Zimmet PZ et al. Retinal arteriolar caliber predicts incident retinopathy: the Australian Diabetes, Obesity and Lifestyle (AusDiab) study. Diabetes Care 2008; 31(4): 761-763.
66. Thoumine O, Nerem RM, Girard PR. Changes in organization and composition of the extracellular matrix underlying cultured endothelial cells exposed to laminar steady shear stress. Lab Invest 1995; 73(4): 565-576.
67. Nagaoka T, Yoshida A. Noninvasive evaluation of wall shear stress on retinal microcirculation in humans. Invest Ophthalmol Vis Sci 2006; 47(3): 1113-1119. (Pubitemid 46768347)
68. Stitt AW, Anderson HR, Gardiner TA, Archer DB. Diabetic retinopathy: quantitative variation in capillary basement membrane thickening in arterial or venous environments. Br J Ophthalmol 1994; 78(2): 133-137.
69. Cogan DG, Toussaint D, Kuwabara T. Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol 1961; 66: 366-378.
70. Stitt AW, Jenkins AJ, Cooper ME. Advanced glycation end products and diabetic complications. Expert Opin Investig Drugs 2002; 11(9): 1205-1223. (Pubitemid 35050074)
71. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005; 97(6): 512-523.
72. Lindblom P, Gerhardt H, Liebner S, Abramsson A, Enge M, Hellstrom M et al. Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 2003; 17(15): 1835-1840. (Pubitemid 36944561)
73. Grunwald JE, Brucker AJ, Schwartz SS, Braunstein SN, Baker L, Petrig BL et al. Diabetic glycemic control and retinal blood flow. Diabetes 1990; 39(5): 602-607. (Pubitemid 20223787)
74. Sharma NK, Gardiner TA, Archer DB. A morphologic and autoradiographic study of cell death and regeneration in the retinal microvasculature of normal and diabetic rats. Am J Ophthalmol 1985; 100(1): 51-60.
75. Linskens MH, Harley CB, West MD, Campisi J, Hayflick L. Replicative senescence and cell death. Science 1995; 267(5194): 17.
76. Caballero S, Sengupta N, Afzal A, Chang KH, Li Calzi S, Guberski DL et al. Ischemic vascular damage can be repaired by healthy, but not diabetic, endothelial progenitor cells. Diabetes 2007; 56(4): 960-967. (Pubitemid 46525067)
77. Bhatwadekar AD, Glenn JV, Li G, Curtis TM, Gardiner TA, Stitt AW. Advanced glycation of fibronectin impairs vascular repair by endothelial progenitor cells: implications for vasodegeneration in diabetic retinopathy. Investig Ophthalmol Vis Sci 2008; 49(3): 1232-1241.
78. Dimmeler S, Assmus B, Hermann C, Haendeler J, Zeiher AM. Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: involvement in suppression of apoptosis. Circ Res 1998; 83(3): 334-341. (Pubitemid 28371324)
79. Li M, Zhao MQ, Kumar Durairajan SS, Xie LX, Zhang HX, Kum WF et al. Protective effect of tetramethylpyrazine and salvianolic acid B on apoptosis of rat cerebral microvascular endothelial cell under high shear stress. Clin Hemorheol Microcirc 2008; 38(3): 177-187. (Pubitemid 351185405)
80. Stitt AW, Gardiner TA, Archer DB. Histological and ultrastructural investigation of retinal microaneurysm development in diabetic patients. Br J Ophthalmol 1995; 79(4): 362-367.
81. Pannarale L, Onori P, Ripani M, Gaudio E. Precapillary patterns and perivascular cells in the retinal microvasculature. A scanning electron microscope study. J Anat 1996; 188(Part 3): 693-703. (Pubitemid 26232210)
82. Kern TS, Engerman RL. Vascular lesions in diabetes are distributed non-uniformly within the retina. Exp Eye Res 1995; 60(5): 545-549.
83. Ashton N. Arteriolar involvement in diabetic retinopathy. Br J Ophthalmol 1953; 37(5): 282-292.
84. Rassam SM, Patel V, Chen HC, Kohner EM. Regional retinal blood flow and vascular autoregulation. Eye 1996; 10(Part 3): 331-337. (Pubitemid 26241503)
85. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995; 102(1): 7-16.
86. Girach A, Lund-Andersen H. Diabetic macular oedema: a clinical overview. Int J Clin Pract 2007; 61(1): 88-97. (Pubitemid 46269355)
87. ETDRS. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98(5 Suppl): 766-785.
88. El-Remessy AB, Behzadian MA, Abou-Mohamed G, Franklin T, Caldwell RW, Caldwell RB. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol 2003; 162(6): 1995-2004. (Pubitemid 36613056)
89. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K et al. VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 2001; 42(10): 2408-2413. (Pubitemid 32848873)
90. Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 1997; 38(1): 36-47. (Pubitemid 27051522)
91. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999; 274(33): 23463-23467. (Pubitemid 129529185)
92. Canning P, Glenn JV, Hsu DK, Liu FT, Gardiner TA, Stitt AW. Inhibition of advanced glycation and absence of galectin-3 prevent blood-retinal barrier dysfunction during short-term diabetes. Exp Diabetes Res 2007; 2007: 51837. (Pubitemid 46630109)
93. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002; 16(3): 438-440.
94. Joussen AM, Poulaki V, Qin W, Kirchhof B, Mitsiades N, Wiegand SJ et al. Retinal vascular endothelial growth factor induces intercellular adhesionmolecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol 2002; 160(2): 501-509. (Pubitemid 34160327)
95. Cunningham Jr ET, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D'Amico DJ et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005; 112(10): 1747-1757.
96. Kristinsson JK, Gottfredsdottir MS, Stefansson E. Retinal vessel dilatation and elongation precedes diabetic macular oedema. Br J Ophthalmol 1997; 81(4): 274-278. (Pubitemid 27196755)
97. Lopes de Faria JM, Jalkh AE, Trempe CL, McMeel JW. Diabetic macular edema: risk factors and concomitants. Acta Ophthalmol Scand 1999; 77(2): 170-175. (Pubitemid 29164056)
98. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102(4): 527-532.
99. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102(4): 520-526.
100. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331(22): 1480-1487.
101. Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996; 103(11): 1820-1828. (Pubitemid 26403735)
102. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina 2006; 26(3): 275-278. (Pubitemid 44318179)
103. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998; 125(9): 1591-1598. (Pubitemid 28256727)
104. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007; 171(1): 53-67. (Pubitemid 47339226)
105. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara Tet al. Endogenous VEGF is required for visual function: evidence for a survival role on Muller cells and photoreceptors. PLoS ONE 2008; 3(11): e3554.